Co-Authors
This is a "connection" page, showing publications co-authored by JAMES P ALLISON and MICHAEL CURRAN.
Connection Strength
2.192
-
Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. J Exp Med. 2013 Apr 08; 210(4):743-55.
Score: 0.444
-
Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe". Immunobiology. 2012 Jun; 217(6):590-2.
Score: 0.403
-
Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One. 2011 Apr 29; 6(4):e19499.
Score: 0.388
-
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010 Mar 02; 107(9):4275-80.
Score: 0.357
-
Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res. 2009 Oct 01; 69(19):7747-55.
Score: 0.347
-
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Proc Natl Acad Sci U S A. 2015 Sep 22; 112(38):E5290-9.
Score: 0.131
-
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest. 2006 Jul; 116(7):1935-45.
Score: 0.069
-
Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-?B signaling improves the efficacy of immunotherapy in a brain cancer model. Neurotherapeutics. 2012 Oct; 9(4):827-43.
Score: 0.027
-
Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer. PLoS One. 2012; 7(4):e35222.
Score: 0.026